

Diabetes management

SEPTEMBER 2019

Information was omitted from **Table 1** on page 596 of the article, Makin V, Lansang MC. Diabetes management: beyond hemoglobin A_{1c} (Cleve Clin J Med 2019; 86(9):595–600, doi:10.3949/ccjm.86a.18031.

The sodium-glucose cotransporter 2 (SGLT2) inhibitors pose a low risk of hypoglycemia, and that should have been noted in the table. The corrected table appears below and online.

TABLE 1

Advantages of selected type 2 diabetes drugs

Drug	Cardiovascular benefit	Weight loss	Low risk of hypoglycemia	Low cost
Metformin		Yes	Yes	Yes
Sulfonylureas				Yes
Meglitinides				
GLP-1 agonists	Yes	Yes	Yes	
DPP-4 inhibitors			Yes	Yes
SGLT2 inhibitors	Yes	Yes	Yes	
Thiazolidine-diones			Yes	
Colesevelam			Yes	
Alpha-glucosidase inhibitors			Yes	
Pramlintide		Yes		
Bromocriptine			Yes	
Insulin				Varies by formulation

DPP-4 = dipeptidyl peptidase 4; GLP-1 = glucagon-like peptide 1; SGLT2 = sodium-glucose cotransporter 2